Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895885 | 0.98 | TSHR (0.43) | TSHRACHEG6PDKEAP1NFE2L2 | |
| SCHEMBL1652088 | 0.98 | TSHR (0.43) | TSHRACHEG6PDKEAP1NFE2L2 | |
| SCHEMBL1584748 | 0.95 | TSHR (0.41) | TSHRACHEG6PDKEAP1NFE2L2 | |
| SCHEMBL9652289 | 0.95 | TSHR (0.41) | TSHRACHEG6PDKEAP1NFE2L2 | |
| SCHEMBL28439337 | 0.95 | TSHR (0.41) | TSHRACHEG6PDKEAP1NFE2L2 | |
| SCHEMBL3152593 | 0.95 | TSHR (0.41) | TSHRACHEG6PDKEAP1NFE2L2 | |
| Ammonia Solution, Strong SCHEMBL3156378 | 0.95 | TSHR (0.41) | TSHRACHEG6PDKEAP1NFE2L2 | |
| Ammonia Solution, Strong SCHEMBL3156386 | 0.95 | TSHR (0.41) | TSHRACHEG6PDKEAP1NFE2L2 | |
| SCHEMBL4383783 | 0.95 | TSHR (0.41) | TSHRACHEG6PDKEAP1NFE2L2 | |
| SCHEMBL3157627 | 0.95 | TSHR (0.41) | TSHRACHEG6PDKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1291346-B1 | Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORP (US) | 2005-03-23 | — | — | EP | disclosed |
| US-6617460-B1 | 5-hydrocarbylsulfoxy-4,5,6,7-tetrahydroindol-4-one intermediates useful in the preparation of 1H-indole-3-glyoxamides. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6570023-B1 | Chemical intermediate for drug to threat sepsis shock, rheumatic diseases | ELI LILLY AND COMPANY | 2003-05-27 | — | — | US | disclosed |
| EP-0941994-B1 | Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity | HOFFMANN LA ROCHE (CH) | 2003-05-14 | — | — | EP | disclosed |
| EP-0708768-B1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1291346-A1 | Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1119549-A4 | PROCESS FOR PREPARING 4-SUBSTITUTED-1H-INDOLE-3-GLYOXAMIDES | LILLY CO ELI (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020188122-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2002-12-12 | — | — | US | disclosed |
| EP-1229035-A1 | Imine intermediates for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1227091-A2 | Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2000021929-A1 | PROCESS FOR PREPARING 4-SUBSTITUTED-1H-INDOLE-3-GLYOXAMIDES | ELI LILLY AND COMPANY (US) | 2000-04-20 | — | — | WO | disclosed |
| US-5969184-A | INTERMEDIATES FOR COMPOUNDS WHICH CONTROL PRODUCTION OF EXCESSIVE INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0941994-A1 | Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| US-5670527-A | CYTOKINE INHIBITORS USEFUL IN TREATING ASTHMA, OSTEOPOROSIS, ARTHRITIS, INFLAMMATION, SEPSIS, CARDIOVASCULAR DISORDERS, DIABETES, MULTIPLE SCLEROSIS, SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5663334-A | CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0708768-A4 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0708768-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002591-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | disclosed |
| US-5252629-A | Adhesives for dentin | GC CORPORATION (JP) | 1993-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188122-A1 | Novel compounds | IL2, IFNG, IL1RN | TSHR 3614/4885ACHE 4842/4885G6PD 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.